ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Articles tagged "Medicare"

  • 2020 American Transplant Congress

    Comparative Review of Adult Kidney Transplant Medicare Cost Report Reimbursement in U. S. Transplant Hospitals

    E. Zavala1, J. Rogers2, S. Karp1

    1Vanderbilt University Medical Center, Nashville, TN, 2Transplant Management Group, San Diego, CA

    *Purpose: Medicare organ acquisition reimbursement (MOAR) from the Medicare Cost Report (MCR) includes but is not limited to costs associated with candidate evaluation, maintenance on…
  • 2020 American Transplant Congress

    Characterizing the Impact of Medicaid Expansion on Pediatric Liver Transplantation

    J. D. Motter, A. Kernodle, D. L. Segev, A. B. Massie

    Johns Hopkins University, Baltimore, MD

    *Purpose: Under the Patient Protection and Affordable Care Act (ACA), states have the option to expand Medicaid eligibility (ME) which has allowed for increased access…
  • 2020 American Transplant Congress

    The Importance of Annual Medicare Part D Plan Evaluation

    L. Potter1, E. Garrity2

    1Department of Pharmacy, University of Chicago Medicine, Chicago, IL, 2Transplant Institute, University of Chicago Medicine, Chicago, IL

    *Purpose: The Medicare open enrollment period is from Oct 15 to Dec 7, annually. The purpose of this project was to objectively measure the benefit…
  • 2020 American Transplant Congress

    Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors

    S. Bova1, A. Cameron1, C. Durand1, J. Katzianer2, M. LeGrand2, L. Boyer1, J. Glorioso3, L. P. Toman1

    1The Johns Hopkins Hospital, Baltimore, MD, 2Johns Hopkins Home Care Group, Baltimore, MD, 3Thomas Jefferson Univeristy Hospital, Philadelphia, PA

    *Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…
  • 2019 American Transplant Congress

    Economic Impact of Donor Hepatitis C Kidney Transplantation: A Medicare Cost Analysis

    K. Lentine1, M. Schnitzler2, T. Alhamad3, H. Xiao2, H. Randall2, J. Wellen2, B. Kasiske4, G. Hess5, D. Axelrod6

    1Saint Louis University Medical Center, St. Louis, MO, 2Saint Louis Univ, St. Louis, MO, 3Washington Univ, St. Louis, MO, 4SRTR, Minneapolis, MN, 5Univ of Pennsylvania, Philadelphia, PA, 6Univ of Iowa, Iowa City, IA

    *Purpose: In the era of highly effective direct-acting antiviral agents (DAAs), kidney transplant (KT) from Hepatitis C virus (HCV)-positive donors is increasingly considered as an…
  • 2019 American Transplant Congress

    The Impact of Transplant Hospital Organ Procurement on Medicare Cost Report Reimbursement

    E. Y. Zavala1, J. Rogers2

    1Transplant Center, Vanderbilt University Medical Center, Nashville, TN, 2Transplant Management Group, San Diego, CA

    *Purpose: Medicare organ acquisition reimbursement from the Medicare Cost Report includes costs associated with transplant hospitals acquiring an organ for Medicare transplant patients and the…
  • 2019 American Transplant Congress

    Donor-derived Cell-free Dna In Donor Specific Antibody Positive Kidney Transplant Recipients

    D. Cheng1, X. Li2, T. Jiang2, H. Liu2, Y. Zhou3, H. Shi3

    1National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China, 2Research and Development, AlloDx Biotech Co.Ltd., Suzhou, China, 3Precise Medicine Center, Biology and Science School, JiangSu University, Zhenjiang, China

    *Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker of kidney allograft injury. Studies examining the clinical validity of this biomarker have identified cut off…
  • 2019 American Transplant Congress

    Insurance Status Impacts Treatment for Hepatocellular Carcinoma

    L. Sobotka1, A. Hinton2, L. Conteh1

    1Gastroenterology, Hepatology and Nutrition, The Ohio State Wexner Medical Center, Columbus, OH, 2The Ohio State University, Columbus, OH

    *Purpose: Previous studies have identified treatment disparities in the treatment of hepatocellular carcinoma (HCC) based on insurance status and provider. Recent studies have shown more…
  • 2018 American Transplant Congress

    Taking Your Center's Temperature: Using a Heat Map to Target Your Transplant-Specific Education for Regulatory Compliance

    J. Anderson, D. Cassidy, D. Dubay, P. Hart, A. Hauser, N. Pilch.

    Medical University of South Carolina, Charleston.

    Background: Large, multi-organ transplant centers struggle with implementation of a comprehensive strategy for development and execution of a Transplant-specific education plan. Regulatory requirements for staff…
  • 2018 American Transplant Congress

    Cost Effectiveness of Lifelong Medicare Immunosuppressant Drug Coverage for Kidney Transplant Recipients in the Current Era

    M. Kadatz,1 J. Gill,2 J. Gill,2 K. Scott.3

    1Clinician Investigator Program, University of British Columbia, Vancouver, BC, Canada; 2Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada; 3Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.

    While there is no Medicare time limit for dialysis patients, kidney transplant recipients lose their Medicare coverage 36 months after they receive their transplant. The…
  • 1
  • 2
  • 3
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Penis Transplantation: First U.S. Experience.
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
    • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    This site uses cookies: Find out more.